QCM
ROIV icon

Qsemble Capital Management’s Roivant Sciences ROIV Stock Holding History

Qsemble Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-93,957
Closed -$2.04M – 598
2025
Q4 		$2.04M Buy
+93,957
New +$1.85M 0.17% 190
2025
Q3 		– Sell
-108,838
Closed -$1.23M – 580
2025
Q2 		$1.23M Buy
+108,838
New +$1.18M 0.12% 219

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qsemble Capital Management's ROIV Position: Q1 2026 in Review

Qsemble Capital Management sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 93,957 shares — an estimated $2.04M sold.

Qsemble Capital Management first reported a position in ROIV in Q2 2025 and held it in 2 quarters. The position peaked at $2.04M in Q4 2025. 444 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Qsemble Capital Management reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 93,957 Roivant Sciences shares in Q1 2026, an estimated $2.04M.
  • Qsemble Capital Management first reported a position in Roivant Sciences in Q2 2025 and held it in 2 quarters.
  • Qsemble Capital Management's Roivant Sciences position peaked at $2.04M in Q4 2025.
  • 444 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.